AzTrials
AzTrials

Botulinum Toxin InjectionFEMFALLTOXNCT07108920

Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait

An observational study of Botulinum Toxin Injection and Stiff Knee Gait, run by Hopital Nord Franche-Comte at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Patients who suffered a stroke, cranial traumatism, medullar lesions or multiple sclerosis can present spastic muscular complications, which is particularly impairing if it concerns muscles of the leg. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Functional clinical tests
How many people
15 participants
Where
1 siteFrance
Study dates
1 Oct 2025to 1 Aug 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The patients consists in patients suffering from a stiff knee gait (SKG) after a stroke, a post-traumatic cerebral lesion or a multiple sclerosis, and who never underwent any neurosurgical procedure and didn't ever change their anti-spastic treatments. Those patients will be seen only in hospital structure (readaptation center) and never outside (liberal practice).

Who may be able to join

  • Patient with a stif knee gait (SKG) after a stroke, a post-traumatic cerebral lesion or a multiple sclerosis.
  • If the patient had a stroke, it happened at least 4 month ago (before the inclusion).
  • The patient has a rectus femoris spasticity ≥ 1 on the modified Ashworth Scale with the hip in extension position.
  • A quadricipital muscular force ≥ 2/5 (MRC Scale)
  • The patient didn't receive any botulinum toxin injection during the 3 previous months
  • No modification of any anti-spastic medication during the inclusion in the actual month (Baclofène, Dantrolène).
  • No neurosurgical intervention or ligamentoplasty of the quadricipital ligament during the 6 previous months.
  • No recent knee traumatism with knee instability during the 6 previous weeks.

Who cannot join

  • Other comorbidities invalidating the fonctionnal tests necessary for the study like : decompensated cardiac insufficiency, unstable respiratory insufficiency, coagulation troubles, neurocognitive impairments inhibiting the comprehension of isocinetical tests.
  • Patient without severe phasic trouble inhibiting the patient's ability to answer the evaluation scales.
  • Sensory lesions inhibiting the possibility to evaluate the walk : visual impairment, major proprioception impairment, or cerebellar ataxia.
  • Severe muscular deficit : genetic myopathy, psychomotric desadaptation syndrom
  • Absolute contraindication to botulinum toxin injections : urinary tract infection ; current treatment by aminoglycosidic antibiotics, severe myasthenia, urine retention in patient who can't receive a urinary catheter.
  • Patient with cognitive troubles compromitting the understanding and the realization of the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jean-Philippe JP Ehny, M.D contact

+33 84 46 57 91

JPEHNY@fondation-arcenciel.fr

France1 site, 1 recruiting
  • Centre de Médecine Physique et de Réadaptation Bretegnier

    Héricourt, Nord Franche-Comté, 70 400

    Jean-Philippe JP Ehny, M.D, +33 84 46 57 91, JPEHNY@fondation-arcenciel.fr

    Jean-Philippe JP Dr. Ehny, M.D

    Recruiting

Other trials in France

About this study

Official title: Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait: What About the Risk of Falls?

Patients who suffered a stroke, cranial traumatism, medullar lesions or multiple sclerosis can present spastic muscular complications, which is particularly impairing if it concerns muscles of the leg. Muscular spastic complications of the legs can alter significantly the ability to walk because it clinically manifests itself by a stiffness of the leg, thus generating a complication called "Stif Knee Gait" (SKG). It means that the femoro-patello-tibial articulation cannot be mobilized as it should because it stays spastic instead of being mobile.

However, it remains possible to treat this kind of medical condition by using Botulinum toxin injections in the target muscle, in particular the rectus femoris (which is part of the quadriceps).

Read more

As a reminder, botulinum toxin, sold under the international common denomination "Botox®", is a neurotoxin of 150 kDa produced by the bacteria "Clostridium Botulinum" and is the most powerful natural poison known to humankind, with its DL50 between 1 and 2 nanogramms / kg in humans. This toxin works by entering the neuro-muscular synaptic junctions and by linking itself to a proteic complex called SNARE. The link between the toxin and the SNARE complex inhibits the fusion of the acetylcholinergic synaptic vesicles with the plasmic membrane of the pre-synaptic axone. The Botox® blocks the exocytosis of the acetycholin (Ach) vesicle in the inter-synaptic space at the neuro-muscular junction and blocks the nervous transmission, thus generating muscular flaccid paralysis. This kind of intoxication is caused directly by an infection by Clostridium Botulinum and is called Botulism. It manifests itself clinically by flaccid paralysis, swelling, diarrhea tiredness, respiratory failure, vomiting etc…

Despite its highly toxic properties, Botox® can be used as a therapeutic tool against number of medical conditions (strabismus, hyperhidrosis, migraines etc…) and even as a cosmetic tool (anti face-wrinkles). It can be used against spastic muscular paralysis, especially like the ones encountered in the patients of this study.

The current Standard Of Care (SOC) against SKG is to inject Botox into the rectus femoris in order to counter its spasticity. It has been shown to upgrade the walking ability of SKG patients by enhancing the leg kinetics. More precisely, it has been shown to improve the fluidity of the movement of the spastic leg in SKG patients, especially the knee flexion. However, the rectus femoris' contractility remains necessary to be able to stand up statically and to stay balanced during the walk and everyday-activity and the myorelaxant properties of Botox® may be problematic and alter the leg biomechanics despite its utility. To this day, no study has been published to compare the static and dynamic balance troubles before and after Botox injections in the rectus femoris.

The medical bibliography does not report any augmentation of the risk of fall in the case of Botox injection in the rectus femoris. However, we consider the hypothesis along which those injections can enhance the risk of fall. Therefore, we decided to conduct a monocentric, prospective observational clinical study to compare the state of the static and dynamic balance before and after Botox injections in the rectus femoris (in SKG patients) by using balance scores.

In order to complete this objective, we compared the following parameters before and after the Botox injection in SKG patients :

  • Time Up and Go test(in seconds) : primary evaluation criteria
  • Berg Balance Scale (BBS) : secondary evaluation criteria
  • Stair climb and descent time test (SCT) : secondary evaluation criteria.
  • Number of falls.
Being tested
Functional clinical tests
Keywords
Botulinum toxin injection, Rectus femoris, Balance troubles, Fall risk analysis, Stiff knee gait patients.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Functional clinical testsOther

    Functional clinical tests:

    • Time Up and Go test
    • Berg Balance Scale (BBS)
    • Stair climb and descent time test (SCT)
    • Number of falls via a questionnaire
Study groups in NCT07108920
Study groupRoleWhat they receive
Patients treated with botulinum toxin injection in the rectus femoris.Not described
Receives: Other: Functional clinical tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time Up and Go test.

    This examination consist in 6 steps :

    1. Sit on a chair
    2. Stand up
    3. Walk 3 meters
    4. Make a U-turn
    5. Walk back to the chair
    6. Sit back.

    The investigator mesures (with a chronometer) the time it takes for the patient to complete the test. The timer starts when the patient stands up, and stops when the patient sits back.

    Measured: Realized only once 4 weeks after the inclusion visit.

Secondary outcomes (1)
  1. Assessment of Berg Balance Scale test.

    The Berg Balance Scale tests consists in assessing the ability of the patient to perform 14 tasks :

    • 1 : to stand up of a chair without using hands
    • 2 : to stand up without support
    • 3 : To sit without support, feet on the floor

    Measured: 4 weeks after the Botulinum toxin injection visit.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2025
  2. Study start1 Oct 2025 (estimated)
  3. Primary completion1 Aug 2026 (estimated)
  4. Study completion1 Aug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07108920
Sponsor's protocol ID
2024-07-FEMFALLTOX
Acronym
FEMFALLTOX
Status last verified
Jul 2025
First submitted
31 Jul 2025
Last updated
22 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Botulinum Toxin Injection and Stiff Knee Gait, run by Hopital Nord Franche-Comte at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jean-Philippe JP Ehny, M.D (+33 84 46 57 91, JPEHNY@fondation-arcenciel.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time Up and Go test. (time frame: Realized only once 4 weeks after the inclusion visit.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in